WILMS TUMOR

This early-phase study tests a new type of immunotherapy for adults with solid tumors that have a specific marker called GPC3. The treatment involves taking a patient's own T cells, adding genes to help them recognize and attack cancer cells, and then giving them back. The study …

This early-stage trial tests a treatment where a child's own immune cells are collected, modified to better attack cancer, and given back as a one-time infusion. It is for children and young adults up to age 21 with solid tumors that have come back or not responded to standard th…

This study tests whether a precise type of radiation called proton beam therapy can treat Wilms tumor while better protecting nearby healthy organs and helping the body grow more normally. About 260 children with newly diagnosed Wilms tumor who need abdominal radiation will take …

This early-phase study tests a combination of two types of immune cells (B7-H3 CAR T cells and PRAME-specific T cells) in children with relapsed or treatment-resistant cancers like rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, and Wilms tumor. The main goal is to check safety a…

This study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain cancers (like head and neck, brain, or kidney tumors) that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug i…

This early-phase study tests a four-drug combination (vorinostat, vincristine, irinotecan, and temozolomide) in children, teens, and young adults up to age 30 whose solid tumors or brain cancers have returned or not responded to standard treatment. The main goals are to find a sa…

This study tests a drug called selinexor in children and young adults whose Wilms tumor or other solid tumors have come back or not responded to treatment. The goal is to see if the drug can shrink or control the tumors. About 45 participants will receive the drug, and doctors wi…

This study tests a special low-dose chemotherapy schedule (metronomic chemo) in children aged 1.5 to 17 years whose Wilms tumor has come back or not responded to standard treatments. The goal is to see if this approach can control the disease after two treatment cycles. About 28 …

This early-stage trial tests a new type of immunotherapy for children and young adults with certain solid tumors that have come back or not responded to treatment. The therapy uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer c…

This early-phase trial tests a new experimental treatment called CARE T cells for children and young adults with certain solid tumors (like liver cancer or Wilms tumor) that have returned or not responded to standard therapy. The treatment involves taking a patient's own immune c…

This study tests a drug called tegavivint in children, teens, and young adults (ages 1 to 30) whose solid tumors have returned or are not responding to standard treatments. The drug works by blocking a key signal that tells cancer cells to grow. The trial aims to find the safest …

This study is testing a precise type of radiation called proton therapy for children and young adults with kidney tumors like Wilms tumor. The goal is to see if this approach causes fewer short-term side effects compared to standard radiation. About 28 participants under 30 years…